Company Profile
Rocket Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- RCKT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.54 USD (+1.14%)
Close
Last updated: August 6, 2026
316M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, RCKT closed up 1.14% at $3.54. No new same-company headline was identified in the current news window.
Company overview
Gene Therapies for Rare Disease
Rocket Pharmaceuticals develops gene therapies for rare hematologic and cardiovascular disorders using lentiviral and adeno-associated-virus vectors.
Commercial Hematology Franchise
KRESLADI is an ex vivo lentiviral gene therapy approved for severe leukocyte adhesion deficiency type I. It represents Rocket's first commercial product.
RP-A501
RP-A501 is an AAV gene therapy in pivotal Phase 2 development for Danon disease, a severe inherited cardiomyopathy caused by mutations in the LAMP2 gene.
RP-A701
RP-A701 is an AAV gene therapy for BAG3-related dilated cardiomyopathy and is preparing to enter first-in-human testing.
Future catalysts
First patient dosing in the Phase 1 study of RP-A701 around mid-2026.
Recent news
- 01
- 02
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Source: Rocket Pharmaceuticals
- 03
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Source: Rocket Pharmaceuticals
- 04
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Source: Rocket Pharmaceuticals
- 05
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
Source: Rocket Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Rocket Pharmaceuticals (RCKT)?
Rocket Pharmaceuticals (RCKT) most recently closed at 3.54 USD, a +1.14% move versus the previous session.
What is the market cap of Rocket Pharmaceuticals (RCKT)?
Rocket Pharmaceuticals currently has a market capitalization of 316M USD on BioPharmSignal.
What does Rocket Pharmaceuticals do?
Gene Therapies for Rare Disease Rocket Pharmaceuticals develops gene therapies for rare hematologic and cardiovascular disorders using lentiviral and adeno-associated-virus vectors. Commercial Hematology Franchise KRESLADI is an ex vivo lentiviral gene therapy approved for severe leukocyte adhesion deficiency type I. It represents Rocket's first commercial...
On which exchange is RCKT stock listed?
Rocket Pharmaceuticals (RCKT) is associated with NASDAQ, United States, Biopharma.
What is RP-A501?
RP-A501 RP-A501 is an AAV gene therapy in pivotal Phase 2 development for Danon disease, a severe inherited cardiomyopathy caused by mutations in the LAMP2 gene.
Which conditions is Rocket Pharmaceuticals targeting with RP-A501?
Rocket Pharmaceuticals is associated with rare disease, cardiovascular disease, hematology based on its company overview and current catalyst commentary.
How does Rocket Pharmaceuticals describe recent progress with RP-A501?
First patient dosing in the Phase 1 study of RP-A701 around mid-2026.
What is RP-A701?
RP-A701 RP-A701 is an AAV gene therapy for BAG3-related dilated cardiomyopathy and is preparing to enter first-in-human testing.